A Phase 2a, 4-Week, Single Arm, Open-label, Multi-center Study to Assess Safety, Tolerability, and Preliminary Efficacy of NOE-115 in Women With Vasomotor Symptoms Due to Menopause
Latest Information Update: 13 May 2025
At a glance
- Drugs NOE 115 (Primary)
- Indications Binge-eating disorder; Depressive disorders
- Focus Adverse reactions
- Sponsors Noema Pharma
Most Recent Events
- 06 May 2025 Planned End Date changed from 30 Apr 2025 to 30 Sep 2025.
- 06 May 2025 Planned primary completion date changed from 30 Apr 2025 to 30 Jul 2025.
- 06 May 2025 Status changed from recruiting to active, no longer recruiting.